Oncternal Therapeutics Inc - Understand $onct stock

$ONCT Market Cap: $4.883 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$1.846M

TTM

Gross Margin

Net Earnings

-$35.97M

TTM

Current Assets

$23.26M

Q2 2024

Current Liabilities

$8.055M

Q2 2024

Current Ratio

288.73%

Q2 2024

Total Assets

$23.86M

Q2 2024

Total Liabilities

$8.105M

Q2 2024

Book Value

$15.75M

Q2 2024

Cash

$6.382M

Q2 2024

P/E

-0.1358

Sep 18, 2024 EST

Free Cash Flow

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Revenue	$785.0K	$1.490M	$4.315M	$3.375M	$2.425M	$2.521M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$8.070M	$1.220M	$14.73M	$13.53M	$7.130M	$7.510M	$3.780M	$1.870M	$0.00	$0.00	$0.00
YoY Change	-47.32%	-65.47%	27.85%	39.18%	-3.81%							-100.0%	561.48%	-91.72%	8.87%	89.76%	-5.06%	98.68%	102.14%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Revenue	$785.0K	$1.490M	$4.315M	$3.375M	$2.425M	$2.521M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$8.070M	$1.220M	$14.73M	$13.53M	$7.130M	$7.510M	$3.780M	$1.870M	$0.00	$0.00	$0.00
Cost Of Revenue															$1.290M	$650.0K	$620.0K	$770.0K	$1.570M	$0.00
Gross Profit															$13.44M	$12.88M	$6.510M	$6.730M	$2.210M	$1.870M
Gross Profit Margin															91.24%	95.2%	91.3%	89.61%	58.47%	100.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Selling, General & Admin	$12.75M	$13.46M	$11.60M	$8.370M	$7.290M	$9.390M	$9.190M	$8.710M	$8.230M	$9.480M	$11.28M	$10.85M	$12.03M	$13.19M	$27.78M	$23.14M	$13.67M	$11.35M	$9.850M	$7.210M	$3.560M	$2.450M	$2.190M
YoY Change	-5.28%	16.06%	38.53%	14.81%	-22.36%	2.18%	5.51%	5.83%	-13.19%	-15.96%	3.96%	-9.81%	-8.79%	-52.52%	20.05%	69.28%	20.44%	15.23%	36.62%	102.53%	45.31%	11.87%	82.5%
% of Gross Profit															206.7%	179.66%	209.98%	168.65%	445.7%	385.56%
Research & Development	$29.75M	$0.00	$0.00	$0.00	$0.00	$0.00	$21.47M	$17.23M	$13.61M	$20.87M	$32.32M	$38.89M	$31.94M	$28.50M	$32.34M	$44.26M	$38.51M	$33.90M	$30.92M	$17.95M	$10.78M	$9.570M	$5.740M
YoY Change						-100.0%	24.61%	26.6%	-34.79%	-35.42%	-16.89%	21.76%	12.08%	-11.89%	-26.93%	14.93%	13.6%	9.64%	72.26%	66.51%	12.64%	66.72%	114.18%
% of Gross Profit															240.63%	343.63%	591.55%	503.71%	1399.1%	959.89%
Depreciation & Amortization						$50.00K	$50.00K	$30.00K	$40.00K	$100.0K	$384.0K	$750.0K	$1.040M	$1.573M	$1.790M	$1.560M	$1.150M	$1.140M	$1.040M	$480.0K	$360.0K	$330.0K	$220.0K
YoY Change						0.0%	66.67%	-25.0%	-60.0%	-73.96%	-48.8%	-27.88%	-33.88%	-12.12%	14.74%	35.65%	0.88%	9.62%	116.67%	33.33%	9.09%	50.0%	175.0%
% of Gross Profit															13.32%	12.11%	17.67%	16.94%	47.06%	25.67%
Operating Expenses	$42.50M	$46.44M	$0.00	$20.92M	$35.53M	$10.11M	$30.66M	$25.93M	$21.84M	$30.35M	$43.60M	$49.73M	$43.97M	$41.69M	$60.12M	$67.40M	$52.18M	$45.25M	$40.77M	$25.16M	$14.34M	$12.02M	$8.150M
YoY Change	-8.48%		-100.0%	-41.13%	251.57%	-67.04%	18.24%	18.73%	-28.04%	-30.39%	-12.33%	13.12%	5.46%	-30.66%	-10.8%	29.17%	15.31%	10.99%	62.04%	75.45%	19.3%	47.48%	105.81%
Operating Profit	-$41.71M	-$44.95M	-$31.37M	-$17.54M	-$33.11M						-$43.60M	-$49.73M	-$35.90M	$15.10M	-$46.68M	-$54.52M	-$45.67M	-$38.52M	-$38.56M	-$23.29M
YoY Change	-7.19%	43.3%	78.81%	-47.02%							-12.33%	38.53%	-337.79%	-132.34%	-14.38%	19.38%	18.56%	-0.1%	65.56%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Interest Expense	$2.235M	$777.0K	$33.00K	$20.00K	$190.0K	$1.000K												$3.010M	$1.720M	$950.0K	$140.0K	$160.0K	$80.00K
YoY Change	187.64%	2254.55%	65.0%	-89.47%	18900.0%													75.0%	81.05%	578.57%	-12.5%	100.0%	-46.67%
% of Operating Profit
Other Income/Expense, Net			$0.00	$317.0K	-$1.080M	$640.0K	$220.0K	$8.210M	$3.140M	-$9.060M	$1.488M	-$19.00K	$398.0K	$1.363M	$190.0K	$2.740M	$5.310M
YoY Change			-100.0%	-129.35%	-268.75%	190.91%	-97.32%	161.46%	-134.66%	-708.87%	-7931.58%	-104.77%	-70.8%	617.37%	-93.07%	-48.4%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Pretax Income	-$39.48M	-$44.17M	-$31.33M	-$17.23M	-$34.19M	-$38.42M	-$30.44M	-$17.72M	-$18.70M	-$39.41M	-$42.11M	-$49.75M	-$35.50M	$16.46M	-$46.49M	-$51.78M	-$40.36M	-$35.51M	-$36.84M	-$22.35M	-$14.19M	-$11.87M	-$8.060M
YoY Change	-10.62%	40.97%	81.85%	-49.61%	-11.01%	26.22%	71.78%	-5.24%	-52.55%	-6.41%	-15.36%	40.14%	-315.68%	-135.41%	-10.22%	28.3%	13.66%	-3.61%	64.83%	57.51%	19.55%	47.27%	111.55%
Income Tax	$0.00	$0.00	$0.00							$0.00	$0.00	-$8.821M	-$886.0K	$0.00	-$240.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income														0.0%
Net Earnings	-$39.48M	-$44.17M	-$31.33M	-$17.23M	-$34.19M	-$6.579M	-$30.44M	-$17.72M	-$18.70M	-$39.41M	-$42.11M	-$27.08M	-$33.29M	$15.29M	-$46.26M	-$51.78M	-$40.36M	-$35.51M	-$36.84M	-$22.35M	-$14.19M	-$11.87M	-$8.060M
YoY Change	-10.62%	40.97%	81.9%	-49.62%	419.65%	-78.39%	71.78%	-5.24%	-52.55%	-6.41%	55.53%	-18.68%	-317.69%	-133.06%	-10.66%	28.3%	13.66%	-3.61%	64.83%	57.51%	19.55%	47.27%	111.55%
Net Earnings / Revenue	-5029.17%	-2964.43%	-726.14%	-510.37%	-1409.81%	-260.97%							-412.57%	1253.61%	-314.05%	-382.71%	-566.06%	-472.84%	-974.6%	-1195.19%
Basic Earnings Per Share	-$13.43	-$0.84	-$0.64
Diluted Earnings Per Share	-$13.43	-$0.84	-$635.3K	-$848.4K	-$3.310M	-$235.1K	-$1.745M	-$1.217M	-$1.332M	-$4.818M	-$6.674M	-$4.312M	-$5.800M	$3.931M	-$12.71M	-$14.26M	-$11.56M	-$11.38M	-$14.17M	-$9.717M	-$18.43M	-$15.42M	-$10.47M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Cash & Short-Term Investments	$34.26M	$63.72M	$90.77M	$116.7M	$20.10M	$28.50M	$43.90M	$21.90M	$29.30M	$49.30M	$14.70M	$56.10M	$74.40M	$58.60M	$49.00M	$97.70M	$110.0M	$119.6M	$74.00M	$64.50M	$14.80M	$8.900M	$8.800M
YoY Change	-46.24%	-29.79%	-22.22%	480.6%	-29.47%	-35.08%	100.46%	-25.26%	-40.57%	235.37%	-73.8%	-24.6%	26.96%	19.59%	-49.85%	-11.18%	-8.03%	61.62%	14.73%	335.81%	66.29%	1.14%
Cash & Equivalents	$6.697M	$37.14M	$90.77M	$116.7M	$20.10M	$28.30M	$15.80M	$8.900M	$14.10M	$17.90M	$14.50M	$48.00M	$63.70M	$58.20M	$40.20M	$95.50M	$100.2M	$119.6M	$74.00M	$64.50M	$14.80M	$8.900M	$8.800M
Short-Term Investments	$27.56M	$26.58M				$200.0K	$28.10M	$13.00M	$15.20M	$31.40M	$200.0K	$8.000M	$10.70M	$500.0K	$8.800M	$2.200M	$9.800M	$0.00
Other Short-Term Assets	$1.172M	$3.388M	$2.088M	$1.300M	$700.0K	$2.800M	$2.200M	$2.400M	$2.600M	$900.0K	$400.0K	$700.0K	$1.300M	$900.0K	$900.0K	$1.000M	$1.400M	$1.200M	$1.700M	$1.200M	$300.0K	$0.00	$0.00
YoY Change	-65.41%	62.26%	60.62%	85.71%	-75.0%	27.27%	-8.33%	-7.69%	188.89%	125.0%	-42.86%	-46.15%	44.44%	0.0%	-10.0%	-28.57%	16.67%	-29.41%	41.67%	300.0%
Inventory													$200.0K	$200.0K	$100.0K	$100.0K	$100.0K	$200.0K	$100.0K	$400.0K	$0.00	$0.00	$200.0K
Prepaid Expenses
Receivables													$1.000M	$700.0K	$600.0K	$1.300M	$40.80M	$700.0K	$200.0K	$0.00
Other Receivables													$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$36.06M	$67.29M	$92.85M	$118.0M	$20.80M	$31.20M	$46.10M	$24.30M	$31.90M	$50.20M	$15.20M	$56.80M	$76.80M	$60.40M	$50.70M	$100.0M	$152.3M	$121.7M	$76.00M	$66.20M	$15.00M	$9.000M	$9.000M
YoY Change	-46.41%	-27.53%	-21.31%	467.31%	-33.33%	-32.32%	89.71%	-23.82%	-36.45%	230.26%	-73.24%	-26.04%	27.15%	19.13%	-49.3%	-34.34%	25.14%	60.13%	14.8%	341.33%	66.67%	0.0%
Property, Plant & Equipment	$258.0K	$87.00K	$75.00K	$0.00	$200.0K	$0.00	$100.0K	$100.0K	$0.00	$0.00	$100.0K	$500.0K	$1.100M	$2.000M	$3.300M	$4.000M	$2.300M	$1.900M	$1.700M	$1.500M	$800.0K	$1.100M	$1.100M
YoY Change	196.55%	16.0%		-100.0%		-100.0%	0.0%			-100.0%	-80.0%	-54.55%	-45.0%	-39.39%	-17.5%	73.91%	21.05%	11.76%	13.33%	87.5%	-27.27%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$412.0K	$1.274M	$657.0K	$800.0K	$800.0K									$0.00			$700.0K	$1.400M	$100.0K	$500.0K	$1.500M	$0.00
YoY Change	-67.66%	93.91%	-17.88%	0.0%													-50.0%	1300.0%	-80.0%	-66.67%
Total Long-Term Assets	$670.0K	$1.361M	$732.0K	$800.0K	$900.0K	$100.0K	$100.0K	$200.0K	$100.0K	$500.0K	$400.0K	$1.000M	$1.900M	$3.900M	$7.000M	$8.100M	$7.400M	$7.600M	$6.800M	$6.900M	$2.300M	$1.000M	$1.100M
YoY Change	-50.77%	85.93%	-8.5%	-11.11%	800.0%	0.0%	-50.0%	100.0%	-80.0%	25.0%	-60.0%	-47.37%	-51.28%	-44.29%	-13.58%	9.46%	-2.63%	11.76%	-1.45%	200.0%	130.0%	-9.09%
Total Assets	$36.73M	$68.65M	$93.59M	$118.8M	$21.70M	$31.30M	$46.20M	$24.50M	$32.00M	$50.70M	$15.60M	$57.80M	$78.70M	$64.30M	$57.70M	$108.1M	$159.7M	$129.3M	$82.80M	$73.10M	$17.30M	$10.00M	$10.10M
YoY Change
Accounts Payable	$1.148M	$2.917M	$1.959M	$1.100M	$900.0K	$3.300M	$2.600M	$1.200M	$400.0K	$500.0K	$800.0K	$1.700M	$1.200M	$800.0K	$1.300M	$2.800M	$1.600M	$1.300M	$1.400M	$900.0K	$500.0K	$600.0K	$300.0K
YoY Change	-60.64%	48.9%	78.09%	22.22%	-72.73%	26.92%	116.67%	200.0%	-20.0%	-37.5%	-52.94%	41.67%	50.0%	-38.46%	-53.57%	75.0%	23.08%	-7.14%	55.56%	80.0%	-16.67%	100.0%
Accrued Expenses	$4.050M	$4.765M	$3.506M	$3.100M	$2.800M	$100.0K	$0.00	$0.00	$300.0K	$400.0K	$1.400M	$300.0K	$4.100M	$3.000M	$4.600M	$6.700M	$6.800M	$3.100M	$3.200M	$2.600M	$1.800M	$700.0K	$200.0K
YoY Change	-15.01%	35.91%	13.1%	10.71%	2700.0%			-100.0%	-25.0%	-71.43%	366.67%	-92.68%	36.67%	-34.78%	-31.34%	-1.47%	119.35%	-3.13%	23.08%	44.44%	157.14%	250.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due													$100.0K	$100.0K	$100.0K	$0.00
YoY Change													0.0%	0.0%
Total Short-Term Liabilities	$5.198M	$7.682M	$5.465M	$5.900M	$7.300M	$5.200M	$8.000M	$4.600M	$30.20M	$32.80M	$4.600M	$9.500M	$5.800M	$5.300M	$16.00M	$21.00M	$19.30M	$10.30M	$6.000M	$4.900M	$2.200M	$1.300M	$500.0K
YoY Change	-32.34%	40.57%	-7.37%	-19.18%	40.38%	-35.0%	73.91%	-84.77%	-7.93%	613.04%	-51.58%	63.79%	9.43%	-66.88%	-23.81%	8.81%	87.38%	71.67%	22.45%	122.73%	69.23%	160.0%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.479M			$0.00	$100.0K				$0.00	$0.00	$400.0K	$600.0K	$900.0K	$7.200M	$50.50M	$55.10M	$61.50M	$21.90M	$3.200M	$4.300M	$0.00
YoY Change				-100.0%						-100.0%	-33.33%	-33.33%	-87.5%	-85.74%	-8.35%	-10.41%	180.82%	584.38%	-25.58%
Total Long-Term Liabilities	$1.479M	$0.00	$0.00	$0.00	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$400.0K	$600.0K	$900.0K	$7.200M	$50.50M	$55.10M	$61.50M	$21.90M	$3.200M	$4.300M	$0.00	$0.00	$0.00
YoY Change				-100.0%						-100.0%	-33.33%	-33.33%	-87.5%	-85.74%	-8.35%	-10.41%	180.82%	584.38%	-25.58%
Total Liabilities	$6.677M	$7.682M	$5.465M	$5.900M	$7.400M	$5.200M	$8.000M	$4.600M	$30.20M	$32.80M	$4.900M	$10.10M	$6.800M	$12.50M	$66.50M	$76.10M	$80.80M	$32.20M	$9.200M	$9.200M	$2.200M	$1.300M	$500.0K
YoY Change	-13.08%	40.57%	-7.37%	-20.27%	42.31%	-35.0%	73.91%	-84.77%	-7.93%	569.39%	-51.49%	48.53%	-45.6%	-81.2%	-12.61%	-5.82%	150.93%	250.0%	0.0%	318.18%	69.23%	160.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	2.940M	52.59M	49.32M
Diluted Shares Outstanding	2.940M	52.59M	49.32M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $4.8834 Million

About Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Industry: Pharmaceutical Preparations Peers: Aligos Therapeutics Inc Ambrx Biopharma Cayman, Inc. Athenex, Inc. Perspective Therapeutics Inc Cidara Therapeutics Inc Sellas Life Sciences Group Inc Scorpius Holdings Inc IN8BIO, Inc. Rubius Therapeutics, Inc.